Hypercalcemia Treatment MarketThe global hypercalcemia treatment market is on track for significant growth, with an estimated valuation of USD 18.07 billion in 2023. The market is projected to expand ...

Amgen investors have been focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

In the last quarter, the company also completed filing for the biosimilar Denosumab in the US and Europe with partner company Alvotech. Dr Reddy's is expecting approvals from the US in 12 months ...